Gossamer Bio, Inc.
GOSS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728117
No open-market purchases or sales by Gossamer Bio, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $75.0M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Gossamer Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Gossamer Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Milligan Sandra | Director | 58,050 | Sep 25, 2026 | 2 |
| Daniel Thomas O | Director | – | Sep 25, 2026 | 2 |
| Ciongoli Gregory Austin | Director | – | Sep 25, 2026 | 1 |
| Drynan Skye | Director | – | Sep 25, 2026 | 2 |
| Quisel John D | Director | – | Sep 25, 2026 | 2 |
| Cox Russell J. | Director | – | Sep 25, 2026 | 2 |
| Nathan Steven D | Director | – | Sep 25, 2026 | 2 |
| Christian Waage | EVP, Tech Ops and Admin | 814,061 | Aug 26, 2026 | 4 |
| Peterson Caryn | Chief Development Officer | 259,333 | Aug 26, 2026 | 4 |
| Smith Robert Paul JR | Chief Commercial Officer | 260,898 | Aug 26, 2026 | 4 |
| Giraudo Bryan | COO/CFO | 389,737 | Aug 26, 2026 | 4 |
| Hasnain Faheem | President & CEO | 837,793 | Aug 26, 2026 | 4 |
| Aranda Richard | Chief Medical Officer | 463,106 | Mar 20, 2026 | 3 |
| Burow Kristina | Director | – | Jun 9, 2023 | 0 |
| Gala Renee D | Director | – | Jun 9, 2023 | 0 |
| Carter Laura | Chief Scientific Officer | 76,263 | Mar 22, 2023 | 0 |
| Bilenker Joshua H. | Director | – | Jul 15, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2025 (view filing) | Aug 19 | 1 day | Milligan SandraDirector | PPurchase | +26.1K | $1.92 | +$50.0K | +81.4%58.0K after | |
| Jun 25, 2024 (view filing) | Jun 24 | 1 day | Aranda RichardChief Medical Officer | SSale | −1.91K | $0.66 | −$1.26K | −1.0%196.9K after | |
| Jun 24, 2024 (view filing) | Jun 21 | 3 days | Hasnain FaheemPresident & CEO | PPurchase | +372.0K | $0.67 | +$249.2K | +7.4%5.41M after | |
| Jun 20, 2024 (view filing) | Jun 18 | 2 days | Giraudo BryanCOO/CFO | PPurchase | +100.0K | $0.59 | +$59.0K | +26.3%480.0K after | |
| Jun 20, 2024 (view filing) | Jun 17 | 3 days | Smith Robert Paul JRChief Commercial Officer | PPurchase | +25.0K | $0.60 | +$15.0K | New position25.0K after | |
| Mar 28, 2024 (view filing) | Mar 27 | 1 day | Christian WaageEVP, Tech Ops and Admin | SSale | −6.43K | $1.16 | −$7.46K | −1.1%585.9K after | |
| Mar 28, 2024 (view filing) | Mar 27 | 1 day | Giraudo BryanCOO/CFO | SSale | −6.43K | $1.16 | −$7.46K | −6.5%92.7K after | |
| Mar 28, 2024 (view filing) | Mar 27 | 1 day | Hasnain FaheemPresident & CEO | SSale | −23.2K | $1.16 | −$26.9K | −16.2%120.3K after | |
| Mar 19, 2024 (view filing) | Mar 18 | 1 day | Aranda RichardChief Medical Officer | SSale | −4.02K | $1.33 | −$5.34K | −2.0%198.8K after | |
| Mar 19, 2024 (view filing) | Mar 18 | 1 day | Peterson CarynEVP, Regulatory Affairs | SSale | −4.02K | $1.33 | −$5.34K | −7.5%49.8K after | |
| Nov 17, 2023 (view filing) | Nov 15 | 2 days | Milligan SandraDirector | PPurchase | +32.0K | $0.79 | +$25.3K | New position32.0K after | |
| Nov 14, 2023 (view filing) | Nov 13 | 1 day | Giraudo BryanCOO/CFO | PPurchase | +200.0K | $0.56 | +$112.0K | +111.1%380.0K after | |
| Jun 26, 2023 (view filing) | Jun 22 | 4 days | Aranda RichardChief Medical Officer | SSale | −1.81K | $1.29 | −$2.34K | −0.9%197.6K after | |
| Apr 5, 2023 (view filing) | Apr 4 | 1 day | Giraudo BryanCOO/CFO | PPurchase | +55.0K | $1.02 | +$56.1K | +77.5%126.0K after | |
| Mar 22, 2023 (view filing) | Mar 20 | 2 days | Christian WaageEVP, Tech Ops and Admin | PPurchase | +18.5K | $1.20 | +$22.2K | +133.2%32.4K after | |
| Mar 22, 2023 (view filing) | Mar 20 | 2 days | Giraudo BryanCOO/CFO | PPurchase | +50.0K | $0.97 | +$48.5K | +238.2%71.0K after | |
| Mar 22, 2023 (view filing) | Mar 20-22 | 2 days | Hasnain FaheemPresident & CEO | PPurchase | +878.6K | $1.14 | +$999.2K | +24.3%4.50M after | 3 lots |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Carter LauraChief Scientific Officer | SSale | −6.03K | $1.10 | −$6.63K | −7.3%76.3K after | |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Aranda RichardChief Medical Officer | SSale | −7.56K | $1.10 | −$8.32K | −3.7%199.4K after | |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Peterson CarynEVP, Regulatory Affairs | SSale | −7.56K | $1.10 | −$8.32K | −12.3%53.9K after | |
| Oct 27, 2022 (view filing) | Oct 24 | 3 days | Carter LauraChief Scientific Officer | SSale | −4.88K | $12.07 | −$58.9K | −5.6%82.3K after | Amended |
| Oct 25, 2022 (view filing) | Oct 24 | 1 day | Peterson CarynEVP, Regulatory Affairs | SSale | −4.76K | $12.07 | −$57.4K | −7.2%61.4K after | |
| Oct 25, 2022 (view filing) | Oct 24 | 1 day | Aranda RichardChief Medical Officer | SSale | −4.76K | $12.07 | −$57.4K | −2.3%205.4K after | |
| Jul 15, 2022 (view filing) | Jul 15 | Same day | Carter LauraChief Scientific Officer | PPurchase | +6.93K | $7.21 | +$50.0K | +8.6%87.2K after | |
| Jul 15, 2022 (view filing) | Jul 15 | Same day | Christian WaageEVP, Tech Ops and Admin | PPurchase | +6.93K | $7.21 | +$50.0K | +99.7%13.9K after | |
| Jul 15, 2022 (view filing) | Jul 15 | Same day | Giraudo BryanCOO/CFO | PPurchase | +13.9K | $7.21 | +$100.0K | +194.8%21.0K after | |
| Jul 15, 2022 (view filing) | Jul 15 | Same day | Hasnain FaheemPresident & CEO | PPurchase | +138.7K | $7.21 | +$1.00M | +4.0%3.62M after | |
| Jul 5, 2022 (view filing) | Jul 1 | 4 days | Carter LauraChief Scientific Officer | SSale | −8.81K | $8.25 | −$72.7K | −9.9%80.2K after | |
| Jun 23, 2022 (view filing) | Jun 22 | 1 day | Aranda RichardChief Medical Officer | SSale | −1.78K | $6.88 | −$12.2K | −0.8%209.9K after | |
| May 5, 2022 (view filing) | May 4 | 1 day | Carter LauraChief Scientific Officer | SSale | −1.26K | $7.20 | −$9.09K | −1.4%89.0K after | |
| Mar 24, 2022 (view filing) | Mar 23 | 1 day | Christian WaageEVP, Tech Ops and Admin | SSale | −10.7K | $8.92 | −$95.6K | −1.8%579.0K after | |
| Mar 24, 2022 (view filing) | Mar 23 | 1 day | Hasnain FaheemPresident & CEO | SSale | −19.0K | $8.92 | −$169.8K | −11.7%143.5K after | |
| Mar 24, 2022 (view filing) | Mar 23 | 1 day | Giraudo BryanCOO/CFO | SSale | −10.7K | $8.92 | −$95.6K | −9.8%99.2K after | |
| Mar 17, 2022 (view filing) | Mar 16 | 1 day | Carter LauraChief Scientific Officer | SSale | −5.00K | $8.28 | −$41.4K | −5.2%90.3K after | |
| Mar 17, 2022 (view filing) | Mar 16 | 1 day | Peterson CarynEVP, Regulatory Affairs | SSale | −6.28K | $8.28 | −$52.0K | −8.7%66.2K after | |
| Mar 17, 2022 (view filing) | Mar 16 | 1 day | Aranda RichardChief Medical Officer | SSale | −6.28K | $8.28 | −$52.0K | −2.9%211.7K after | |
| Oct 26, 2021 (view filing) | Oct 25 | 1 day | Peterson CarynEVP, Regulatory Affairs | SSale | −2.38K | $12.25 | −$29.1K | −3.2%72.5K after | |
| Oct 26, 2021 (view filing) | Oct 25 | 1 day | Carter LauraChief Scientific Officer | SSale | −2.38K | $12.25 | −$29.1K | −2.4%95.3K after | |
| Oct 26, 2021 (view filing) | Oct 25 | 1 day | Aranda RichardChief Medical Officer | SSale | −2.38K | $12.25 | −$29.1K | −1.1%217.4K after |